At a glance
- Originator Oscient Pharmaceuticals
- Class Antibacterials
- Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 23 Nov 2004 Discontinued - Preclinical for Gram-positive infections in USA (unspecified route)
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 12 Feb 2004 GeneSoft has merged with Genome Therapeutics